Riverbridge Partners LLC Sells 34,111 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Riverbridge Partners LLC decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 517,533 shares of the company’s stock after selling 34,111 shares during the period. Medpace comprises approximately 2.3% of Riverbridge Partners LLC’s portfolio, making the stock its 9th largest position. Riverbridge Partners LLC’s holdings in Medpace were worth $171,940,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Iron Triangle Partners LP bought a new stake in shares of Medpace during the third quarter worth $64,371,000. Clearbridge Investments LLC increased its holdings in Medpace by 55.1% during the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock worth $166,343,000 after purchasing an additional 143,481 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Medpace by 62.3% in the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock valued at $127,941,000 after purchasing an additional 119,257 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after purchasing an additional 109,886 shares in the last quarter. Finally, DF Dent & Co. Inc. boosted its position in shares of Medpace by 189.9% during the third quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock worth $53,841,000 after buying an additional 105,659 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Medpace stock opened at $345.18 on Thursday. The company’s 50-day moving average is $339.73 and its 200-day moving average is $356.13. The firm has a market capitalization of $10.73 billion, a PE ratio of 30.23, a P/E/G ratio of 1.78 and a beta of 1.36. Medpace Holdings, Inc. has a fifty-two week low of $286.76 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Medpace’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the company posted $2.22 earnings per share. As a group, analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. UBS Group lowered Medpace from a “buy” rating to a “neutral” rating and dropped their target price for the company from $420.00 to $350.00 in a research report on Friday, September 27th. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and lowered their price objective for the company from $415.00 to $345.00 in a report on Wednesday, September 25th. Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Robert W. Baird raised their target price on shares of Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a research report on Monday, November 25th. Finally, William Blair reissued an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $380.56.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.